NextRNA Therapeutics leverages a proprietary discovery platform to systematically identify disease-relevant long non-coding RNAs and their interacting proteins and to develop selective small molecules that modulate those interactions. The company is advancing a pipeline built from that platform and has progressed two small-molecule programs in oncology and immunology. NextRNA was founded in January 2021 and is based in Cambridge, Massachusetts. Leadership and scientific founders include Carl Novina and Robert Langer, and the company cites pioneering work at Dana-Farber Cancer Institute as its scientific basis. At launch NextRNA intends to use financing proceeds to augment its target and drug discovery engine, expand its pipeline, and advance lead programs. The company positions itself to translate discoveries around long non-coding RNAs into transformative therapies across multiple disease areas.

Total raised

$56M

Funding rounds

2

Latest round

Seed

Latest activity

Mar 2022